Dr. Gregg T. Kokame, the initial founder of HMRI in 1993, trained at the Bascom Palmer Eye Institute (BPEI) in retinal diseases and surgery, and worked with the nation’s #1 ranked ophthalmology program according to US News and World Report for the past 10 years. BPEI was also the birthplace of modern vitreoretinal surgery, and home to some of the most well known retina specialists in the history of ophthalmology, with whom Dr. Kokame worked. Dr. Kokame also did a research sabbatical in both medical and surgical retina at Moorfields Eye Hospital in London, where world renowned retina research has been performed for over at the Institute of Ophthalmology, and where Dr. Kokame worked with some of Europe’s greatest leaders in retinal disease management and research. Dr. Kokame did his ophthalmology residency at the Jules Stein Eye Institute at UCLA in Los Angeles, California, which has always been considered the top ophthalmology program in the western United States.
Currently Dr. Kokame is the Principal Investigator (PI) for the following clinical trials at HMRI: EPIC (Indepedendent Study Trial), CHROMA (Genentech), VAPOR (Santen), HAWK (Alcon), and the Argus II Post Approval Study (Second Sight). He serves as the sub-PI for all other clinical trials at HMRI.
Recently, Dr. Kokame made international news for being the first surgeon to perform the Argus II Bionic Implant in the Asia Pacific region. You can read about it here.
Dr. Kokame is a world leader in polypoidal choroidal vasculopathy, with numerous publications in the field. He has continued the worldwide impact of HMRI’s research by traveling Taiwan and Korea, and lectured on polypoidal choroidal vasculopathy and the drug Eylea.